ACM
AGIO icon

AlphaCrest Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

AlphaCrest Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-26,458
Closed -$748K – 32
2022
Q3 		$748K Sell
26,458
-7,907
-23% -$212K 0.05% 779
2022
Q2 		$762K Buy
34,365
+13,411
+64% +$303K 0.04% 785
2022
Q1 		$610K Sell
20,954
-7,977
-28% -$244K 0.03% 799
2021
Q4 		$951K Buy
28,931
+12,207
+73% +$491K 0.04% 817
2021
Q3 		$772K Buy
16,724
+127
+0.8% +$6.13K 0.04% 730
2021
Q2 		$915K Buy
+16,597
New +$928K 0.04% 706
2021
Q1 		– Sell
-5,460
Closed -$237K – 1168
2020
Q4 		$237K Sell
5,460
-7,840
-59% -$310K 0.02% 1006
2020
Q3 		$466K Buy
13,300
+6,683
+101% +$293K 0.05% 629
2020
Q2 		$354K Buy
+6,617
New +$306K 0.06% 550
2020
Q1 		– Sell
-5,865
Closed -$280K – 1002
2019
Q4 		$280K Buy
+5,865
New +$222K 0.02% 1093
2019
Q3 		– Sell
-17,510
Closed -$873K – 1240
2019
Q2 		$873K Buy
+17,510
New +$936K 0.08% 465

Other funds holding AGIO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AlphaCrest Capital Management's AGIO Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q4 2022, closing a stake of 26,458 shares — an estimated $748K sold.

AlphaCrest Capital Management first reported a position in AGIO in Q2 2019 and held it in 11 quarters. The position peaked at $951K in Q4 2021. 160 funds tracked by Wall St. Rank hold AGIO as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Agios Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 26,458 Agios Pharmaceuticals shares in Q4 2022, an estimated $748K.
  • AlphaCrest Capital Management first reported a position in Agios Pharmaceuticals in Q2 2019 and held it in 11 quarters.
  • AlphaCrest Capital Management's Agios Pharmaceuticals position peaked at $951K in Q4 2021.
  • 160 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.